LVW Advisors
RXRX icon

LVW Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

LVW Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$49.6K Hold
12,000
– – ﹤0.01% 458
2026
Q2 		$44K Buy
+12,000
New +$40K ﹤0.01% 461
2026
Q1 		– Sell
-13,000
Closed -$53.2K – 454
2025
Q4 		$53.2K Hold
13,000
– – 0.01% 341
2025
Q3 		$63.4K Buy
+13,000
New +$68.3K 0.01% 346

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

LVW Advisors's RXRX Position: Q3 2026 in Review

LVW Advisors held its Recursion Pharmaceuticals (RXRX) position steady in Q3 2026 at 12,000 shares worth $49.6K. The position accounts for ﹤0.01% of the portfolio, ranked #458.

LVW Advisors first reported a position in RXRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $63.4K in Q3 2025. 178 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • LVW Advisors held 12,000 shares of Recursion Pharmaceuticals worth $49.6K as of Q3 2026.
  • LVW Advisors left its Recursion Pharmaceuticals share count unchanged in Q3 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of LVW Advisors's portfolio in Q3 2026, its #458 holding.
  • LVW Advisors first reported a position in Recursion Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • LVW Advisors's Recursion Pharmaceuticals position peaked at $63.4K in Q3 2025.
  • 178 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on LVW Advisors's 13F filing for Q3 2026, filed 19 Oct 2026.